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Lipopolysaccharide (LPS), or endotoxin, a structural component of gram-negative bacterial outer
membranes, plays a key role in the pathogenesis of septic shock, a syndrome of severe systemic inflam-
mation which leads to multiple-system organ failure. Despite advances in antimicrobial chemotherapy,
sepsis continues to be the commonest cause of death in the critically ill patient. This is attributable to the
lack of therapeutic options that aim at limiting the exposure to the toxin and the prevention of subsequent
downstream inflammatory processes. Polymyxin B (PMB), a peptide antibiotic, is a prototype small
molecule that binds and neutralizes LPS toxicity. However, the antibiotic is too toxic for systemic use as
an LPS sequestrant. Based on a nuclear magnetic resonance-derived model of polymyxin B-LPS complex,
we had earlier identified the pharmacophore necessary for optimal recognition and neutralization of the
toxin. Iterative cycles of pharmacophore-based ligand design and evaluation have yielded a synthetically
easily accessible N1,mono-alkyl-mono-homologated spermine derivative, DS-96. We have found that DS-96
binds LPS and neutralizes its toxicity with a potency indistinguishable from that of PMB in a wide range
of in vitro assays, affords complete protection in a murine model of LPS-induced lethality, and is
apparently nontoxic in vertebrate animal models.
Endotoxin, or lipopolysaccharide (LPS), a structural com-
ponent of the outer membrane of most gram-negative bacteria
(31), plays a pivotal role in septic shock, a syndrome of sys-
temic toxicity which occurs frequently as a sequel to serious
systemic gram-negative infections (23). The activation by LPS
of the innate immune response, mediated via toll-like receptor
4 (TLR4) (39), leads to a dysregulated production of numerous
inflammatory mediators, including tumor necrosis factor alpha
(TNF-), interleukin-1 (IL-1), and IL-6 (11), gamma inter-
feron (IFN-), and IL-12, which appears to be inadequately
compensated for by the production of anti-inflammatory cyto-
kines, such as IL-10 and transforming growth factor  (6). The
resultant systemic inflammatory response progresses to the
frequently fatal syndrome of multiple-system organ failure (3).
Despite continuing advances in antimicrobial chemotherapy,
the incidence of sepsis has risen almost threefold from 1979
through 2000 (25), emphasizing an urgent, unmet need to
develop therapeutic options specifically targeting the patho-
physiology of sepsis.
The toxicity of LPS resides in its structurally highly con-
served glycolipid component called lipid A (22), which is
composed of a hydrophilic, bis-phosphorylated diglu-
cosamine backbone, and a hydrophobic domain comprised
of acyl chains in amide and ester linkages (14). Polymyxin B
(PMB) is a membrane-active peptide antibiotic (37) known
to sequester LPS and abrogate its toxicity (12, 16). The oto-
and nephrotoxicity of PMB limit its systemic use and have
led to the development of an extracorporeal hemoperfusion
cartridge based on PMB covalently immobilized on a poly-
styrene-based fiber (Toraymyxin; Toray Industries Inc., To-
kyo, Japan) (40). Approved for clinical use in Japan in late
2000, Toraymyxin provides a clinically validated proof-of-
concept of the therapeutic potential of sequestering circu-
lating LPS.
Based on a nuclear magnetic resonance-derived model of
PMB-lipid A complex (2), we had earlier identified the phar-
macophore necessary for optimal recognition and neutraliza-
tion of lipid A (reviewed in reference 8). Iterative cycles of
pharmacophore-based ligand design have yielded an N1,mono-
alkyl-mono-homologated spermine derivative, DS-96 (Fig. 1),
which binds lipid A and neutralizes its toxicity with a potency
indistinguishable from that of PMB, affords complete protec-
tion in a murine model of LPS-induced lethality, and is non-
toxic for vertebrate animal models.
MATERIALS AND METHODS
Reagents. All reagents and chemicals were purchased from Sigma-Aldrich (St.
Louis, MO) unless otherwise specified. LPS from Escherichia coli O111:B4 and
O55:B5 (Ra chemotypes) and E. coli k12 D31m4 (Re chemotype) was purchased
from List Biological Laboratories (Campbell, CA). LPS from Salmonella enterica
serovar Abortus equi, Vibrio cholerae, and Pseudomonas aeruginosa were
procured from Sigma Chemicals (St. Louis, MO). The fluorescent probe,
BODIPY-TR-cadaverine (5-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-
s-indacene-3-yl) phenoxy)acetyl)amino)pentylamine hydrochloride) (BC), was
obtained from Molecular Probes/Invitrogen (Carlsbad, CA).
Binding affinity measurements. The BC displacement assay for quantifying
binding affinity has been described previously (5, 43, 44). Briefly, to the first
column (16 wells) of a Corning Nonbinding Surface 384-well flat-bottom
black fluorescence microplate 80-l aliquots of 1 mM stock solutions of
DS-96 or PMB (reference compound) were added in quadruplicate and were
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serially diluted twofold across the remaining 23 columns in 50 mM Tris buffer,
pH 7.4, using a Precision 2000 automated microplate pipetting system,
achieving a final dilution of 0.112 nM in a volume of 40 l. Forty-microliter
aliquots of a mixture of 50 g/ml of LPS and 5 M BC in buffer were added
to each well of the plate using the Precision 2000 instrument. Fluorescence
measurements were made at 25°C on a SpectraMax M2 multifunction plate
reader (Molecular Devices, Sunnyvale, CA) with excitation and emission
wavelengths at 580 and 620 nm, respectively. Relative binding affinities were
measured as the effective displacement of 50% of bound probe (ED50) using
standard four-parameter logistic curve fitting subroutines in Origin version
7.0 (OriginLab, Northampton, MA). E. coli O111:B4 smooth LPS was used as
the ligand in the BC displacement experiment and as stimuli in all in vitro
activity assays that follow, except in experiments designed to test whether
DS-96 neutralized LPS isolated from diverse, non-E. coli gram-negative bac-
teria (described in relation to NF-B assay, below).
Measurement of NO release in murine macrophages. Nitric oxide (NO) was
measured as total nitrite in murine macrophage J774.A1 cells using the Griess
reagent system (17, 18) as described previously (5, 26). J774.A1 cells were grown
in RPMI-1640 cell culture medium containing L-glutamine and sodium bicar-
bonate and supplemented with 10% fetal bovine serum, 1% L-glutamine-peni-
cillin-streptomycin solution, and 200 g/ml L-arginine at 37°C in a 5%-CO2
atmosphere, plated at 105 cells/ml in a volume of 80 l/well in 384-well,
flat-bottomed, cell culture-treated microtiter plates until confluence, and subse-
quently stimulated with 10 ng/ml LPS. Concurrent with LPS stimulation, serially
diluted concentrations of test compounds were added to the cell medium and left
to incubate overnight for 16 h. PMB was used as the reference compound in each
plate. Positive (LPS stimulation only) and negative controls (J774.A1 medium
only) were included in each experiment. Nitrite concentrations were measured,
adding 50 l of supernatant to equal volumes of Griess reagents (50 l/well;
0.1% NED solution in double-distilled water and 1% sulfanilamide–5% phos-
phoric acid solution in double-distilled water) and incubating for 15 min at room
temperature in the dark. Absorbance at 535 nm was measured using a Molecular
Devices Spectramax M2 multifunction plate reader. Nitrite concentrations were
interpolated from standard curves obtained from serially diluted sodium nitrite
standards.
Multiplexed cytokine assay ex vivo with human blood and with in vivo murine
blood. One-hundred-microliter aliquots of fresh whole blood, anticoagulated
with EDTA, obtained by venipuncture from healthy human volunteers with
informed consent and as per guidelines approved by the Human Subjects Ex-
perimentation Committee, was exposed to an equal volume of 20 ng/ml of E. coli
0111:B4 LPS, with graded concentrations of test compounds diluted in saline for
4 h in a 96-well microtiter plate as described previously (5, 26). The effect of
the compounds on modulating cytokine production was examined using a
FACSArray multiplexed flow-cytometric bead array (CBA) system (Becton-
Dickinson-Pharmingen, San Jose, CA). The system uses a sandwich enzyme-
linked immunosorbent assay-on-a-bead principle (7, 15) and is comprised of six
populations of microbeads that are spectrally unique in terms of their intrinsic
fluorescence emission intensities (detected in the FL3 channel of a standard flow
cytometer). Each bead population is coated with a distinct capture antibody to
detect six different cytokines concurrently from biological samples (the human
inflammation CBA kit includes the following analytes: TNF-, IL-1, IL-6, IL-8,
IL-10, and IL-12p70). The beads are incubated with 30 l of sample, and the
cytokines of interest are first captured on the bead. After the beads are washed,
a mixture of optimally paired second antibodies conjugated to phycoerythrin is
added, which then forms a fluorescent ternary complex with the immobilized
cytokine, the intensity (measured in the FL2 channel) of which is proportional to
the cytokine concentration on the bead. The assay was performed according to
protocols provided by the vendor. Standard curves were generated using recom-
binant cytokines provided in the kit. The data were analyzed using the CBA
software suite that is integral to the FACSArray system. The CBA multiplexed
assay was also used to quantify cytokine production in mouse blood samples (see
below) using the mouse inflammation CBA kit, which includes the following
analytes: TNF-, IL-6, IL-10, macrophage chemotactic protein 1, IFN-, and
IL-12p70.
Inhibition of LPS-induced NF-B induction. The inhibition of induction of
NF-B (a key transcriptional activator of the innate immune system) was quan-
tified using human embryonic kidney 293 cells cotransfected with TLR4 (LPS
receptor) and CD14 and MD2 (coreceptors), available from InvivoGen, Inc.
(HEK-Blue; San Diego, CA), as described elsewhere (24). Stable expression of
secreted alkaline phosphatase (seAP) under control of the NF-B/AP-1 promot-
ers is inducible by LPS, and extracellular seAP in the supernatant is proportional
to NF-B induction. HEK-4 cells were incubated at a density of 105 cells/ml in
a volume of 80 l/well in 384-well, flat-bottomed, cell culture-treated microtiter
plates until confluence was achieved and subsequently stimulated with 10 ng/ml
LPS. Concurrent with LPS stimulation, serially diluted concentrations of test
compounds were added to the cell medium using a rapid-throughput, automated
protocol employing a Bio-Tek P2000 liquid handler as described above and left
to incubate overnight. PMB was used as a reference compound in each plate.
Positive (LPS stimulation only) and negative controls (HEK detection medium
only) were included in each experiment. seAP was assayed spectrophotometri-
cally using an alkaline phosphatase-specific chromogen (present in HEK detec-
tion medium as supplied by the vendor) at 620 nm.
Phosflow flow cytometric assay for p38 MAPK. One-milliliter aliquots of fresh
whole blood, anticoagulated with heparin (obtained by venipuncture from
healthy human volunteers with informed consent and as per guidelines approved
by the Human Subjects Experimentation Committee), were incubated with 25 l
of a mix of 8 g/ml of E. coli 0111:B4 LPS and graded concentrations of test
compounds diluted in saline (typically serially diluted from 80 M) for 15 min at
37°C. This resulted in final concentrations of 100 ng/ml of LPS and 1 nM of
compound (at the lowest dilution). Positive (LPS alone) and negative (saline)
controls were included in each experiment. Erythrocytes were lysed and leuko-
cytes were fixed in one step by mixing 200 l of the samples in 4 ml prewarmed
Whole Blood Lyse/Fix buffer (Becton-Dickinson Biosciences, San Jose, CA).
After the cells were washed at 500  g for 8 min in CBA buffer, the cells were
permeabilized in ice-cold methanol for 30 min, washed twice in CBA buffer,
transferred to a Millipore MultiScreen BV 1.2 filter plate, and stained with
either phycoerythrin (PE)-conjugated mouse anti-p38 mitogen-activated protein
kinase (MAPK) (pT180/pY182; BD Biosciences) monoclonal antibody or a
matched PE-labeled mouse immunoglobulin G1  isotype control monoclonal
antibody for 60 min. The cells were washed twice in the plate by aspiration as
per protocols supplied by the vendor. Cytometry was performed using a BD
FACSArray instrument in the single-color mode for PE acquisition on 20,000
gated events. Postacquisition analyses were performed using FlowJo v 7.0 soft-
ware (Treestar, Ashland, OR).
Murine in vivo experiments. Dose-response and time course experiments with
a D-galactosamine-sensitized mouse model of endotoxic shock were performed
as described elsewhere (5, 26) using a supralethal dose (twice the 100% lethal
dose (LD100), i.e., 200 ng/mouse) of LPS. Female, outbred, 9- to 11-week-old
CF-1 mice (Charles River, Wilmington, MA) weighing 22 to 28 g were used in all
studies. In some experiments, animals were bled by terminal cardiac puncture
under anesthesia at various times following LPS/compound administration for
cytokine analyses using the CBA assay (Mouse Inflammation CBA kit; BD
Biosciences) as described above. For toxicity studies, mice received DS-96 (40
mg/kg of body weight) dissolved in 0.2 ml isotonic saline containing human serum
albumin at 66 mg/ml subcutaneously in the lower flank in a volume of 0.2 ml,
each day for 5 days (200 mg/kg DS-96, total dose), and were monitored for
abnormal external characteristics. Blood was harvested on day 6 via cardiac
puncture under anesthesia into heparin tubes and centrifuged at 4,000 rpm for 10
min. Plasma samples were submitted for testing to University of Missouri Re-
search Animal Diagnostic Laboratory (Columbia, MO) and were also assayed for
polyamine levels. The statistical significance of lethality data was analyzed by
using the 	2 test.
Assay for plasma polyamine levels in mice exposed to high-dose DS-96. One-
hundred-microliter aliquots of either control plasma or DS-96-treated plasma
were placed in separate Eppendorf tubes to which an equal volume of ice-cold
10% trichloroacetic acid was added to precipitate proteins. After incubation at
4°C for 10 min, the tubes were centrifuged at 4°C at 13,000 rpm for 25 min and
then dried in a Speed-Vac concentrator (Thermo Electron Corporation) for 1 h
at 43°C. The precipitate was resuspended in 100 l of a solution of 13.8 mM
fluorescamine (38) in methanol and alkalinized by adding 20 l of 1 M NaOH.
A 1:10 dilution in methanol was injected into an Agilent Stable Bond C18 column
FIG. 1. The chemical structure of DS-96 [N1-(3-aminopropyl)-N4-(3-(3-
(hexadecylamino)-propylamino)propyl)butane-1,4-diamine; pentatrifluoro-
acetate salt].
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(3.0 mm by 150 mm) on a Shimadzu LC-10 HPLC instrument. Peaks were
detected using an SPD-M10 VP diode array detector (
max, 380 nm) and an
RF-10Axl fluorescence detector (
ex  380 nm; 
em  464 nm). Initial column
conditions were 0.1% trifluoroacetic acid in 10% acetonitrile (CH3CN) in 0.1%
trifluoroacetic acid-H2O, increasing to 100% CH3CN over 30 min. The retention
times of fluorescamine-labeled standards (spermine, spermidine, and putrescine)
were 14.292 min, 16.30 min, and 11.267 min, respectively.
RESULTS AND DISCUSSION
Design rationale and synthesis of DS-96. Our identification
of the lipopolyamines as potential endotoxin-sequestering mol-
ecules was based on two simple heuristics which have been
experimentally tested and validated (26): (i) an optimal dis-
tance of 14 Å is necessary between protonatable functions in
linear bis-cationic molecules for simultaneous ionic interac-
tions with the anionic phosphates on lipid A (Fig. 2A), and (ii)
additional, appropriately positioned hydrophobic group(s) are
obligatory for the interaction to manifest in neutralization of
endotoxicity. Leads obtained from high-throughput screening
on focused libraries (4, 44, 45) and from molecular modeling
studies and in silico docking studies (19) suggested that exten-
sion of the spermine backbone and the introduction of an
additional, appropriately positioned amine on the scaffold
would allow favorable salt bridges with the lipid A phosphate
groups, analogous to that observed in complexes of lipid A and
PMB (2), as well as additional H-bond interactions with the
3-deoxy-D-manno-octulosonic acid (KDO) sugars (30) in the
inner-core region of LPS (Fig. 2B). In recent structure-activity
relationship studies, we had determined that C16 hydrophobic
groups are optimal for effective LPS sequestration (5).
FIG. 2. (A) A nuclear magnetic resonance-derived model of the
PMB (stick representation with van der Waals surface)-lipid A (ball-
and-stick) complex (2). Bidentate salt bridges (dotted lines) are pos-
tulated to occur between each phosphate group on lipid A and two
pairs of the -NH2 groups of Dab residues (2). The poly-acyl domain
of lipid A is shown truncated. (B) Molecular-modeling-derived geom-
etry of the complex between LPS and DS-96. The atomic coordinates
of LPS were derived from its crystal structure (14). The mono-homol-
ogated spermine backbone is predicted to form salt bridges with both
phosphate groups on lipid A, as well as participating in additional ionic
H bonds with the inner core KDO sugars.
FIG. 3. (A) Binding affinities of DS-96 and PMB (reference com-
pound) to E. coli O111:B4 LPS determined by BODIPY-cadaverine
displacement assay. The ED50s for the two compounds are 1.2  0.16
M and 1.31  0.12 M, respectively. (B) Inhibitory activity of NO
production by DS-96 and PMB in LPS-stimulated murine J774 mac-
rophage cells. The IC50s for DS-96 and PMB are, respectively, 21  3
nM and 27  2 nM.
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Binding affinity and in vitro neutralization activity. We first
examined quantitatively the binding affinities of DS-96 and
PMB to LPS with an automated fluorescence displacement
assay using BC (43). The ED50 values for DS-96 and PMB
were found to be virtually identical: 1.2  0.16 M and 1.31 
0.12 M, respectively (Fig. 3A). Murine but not human mono-
cytes produce measurable quantities of NO, an important sur-
rogate marker of immune activation by bacterial products (42).
DS-96 and PMB inhibited NO production in a concentration-
dependent manner in murine J774A.1 cells stimulated with 10
ng/ml LPS, with the 50% inhibitory concentrations (IC50s) for
DS-96 and PMB being 21  3 nM and 27  2 nM, respectively
(Fig. 3B).
The nuclear translocation of NF-B is a key transcriptional
activation event that occurs in response to noxious stimuli.
NF-B induction is upstream of a plethora of signaling cas-
cades, which include the production of cytokines and other
proinflammatory molecules. True sequestration of LPS should
therefore result in the inhibition not only of NF-B induction
but also of downstream cellular responses. Furthermore, a
compound that specifically antagonizes the effects of LPS
should cause inhibition of NF-B induction and cognate sig-
naling events as a response to LPS but not other stimuli. We
used HEK-Blue (Invivogen, San Diego, CA) cells (human em-
bryonic kidney 293 cells stably transfected with a seAP reporter
gene under the control of NF-B/AP-1 promoters along with
the LPS receptor [TLR4] and coreceptors [CD-14 and MD-2])
(24). DS-96 and PMB inhibited LPS-induced NF-B induction
with virtually indistinguishable IC50s (32  2 nM) but showed
no inhibitory effect on TNF--stimulated cells (Fig. 4). Speci-
ficity of action for both PMB and DS-96 could also be demon-
strated by showing that the IC50s were inversely related to the
stimulus (LPS) concentration in a Schild-type plot (Fig. 5A). Both
compounds were also without effect on a range of non-LPS stim-
uli, such as TNF- (Fig. 4), phorbol esters, ionomycin, and IL-1
(data not shown), demonstrating that the mechanism of action of
PMB and DS-96 was by sequestration of LPS.
An ideal LPS sequestrant of potential clinical utility should be
one which binds to and neutralizes a wide range of endotoxins
from different gram-negative bacteria. Although the lipid A por-
tion of LPS is structurally highly conserved (32), substoichiomet-
ric substitutions on the phosphate group with aminoarabinose or
phosphoethanolamine (27), as seen, for example, in Salmonella
enterica serovar Typhimurium, can significantly alter the binding
FIG. 4. Inhibition of NF-B reporter gene induction in HEK-293
cells stably transfected with TLR4/CD-14/MD-2/NF-B–SEAP con-
struct. Cells were stimulated with either LPS (10 ng/ml) or recombi-
nant human TNF- (100 ng/ml) and exposed to graded concentrations
of test compounds. Both DS-96 and PMB inhibit LPS-stimulated
NF-B induction with identical potencies (IC50, 32  2 nM) but show
no effect on TNF--stimulated cells, showing specificity of action.
Shown on the left are negative and positive (LPS alone and TNF-
alone) controls.
FIG. 5. (A) Schild-type analysis of dependence of IC50 (NF-B
induction) of DS-96 and PMB on the dose of LPS used. HEK-4 cells
were stimulated with escalating (1 ng/ml to 10 g/ml) doses of E. coli
O111:B4 LPS, preincubated with graded doses of either PMB or DS-
96. IC50s for either compound were determined at each LPS stimulus
dose. (B) Inhibition of NF-B reporter gene induction by DS-96 and
PMB in HEK-293 cells stimulated with 10 ng/ml LPS isolated from a
wide variety of gram-negative bacteria. A stimulus of 10 ng/ml LPS was
used. Note that the IC50s for both PMB and DS-96 are very similar,
irrespective of the source of LPS. With serovar Abortus equi LPS as
stimulus, DS-96 was observed to be more potent (IC50, 82 nM) than
PMB (IC50, 562 nM).
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of cationic antimicrobials, such as PMB (21). We therefore ex-
amined if DS-96 would effectively neutralize a broad range of LPS
(E. coli 0111:B4, E. coli 055:B5, serovar Abortus equi, P. aerugi-
nosa, and V. cholerae) in the NF-B assay. We found that this was
indeed the case (Fig. 5B), with the IC50s being very similar for
most LPS species (30 nM). Interestingly, we also observed that
DS-96 was approximately eightfold more potent than PMB in
inhibiting serovar Abortus LPS (Fig. 5B).
FIG. 6. (A) Inhibition of phosphorylation of p38 MAP kinase in neutrophils in whole human blood (ex vivo), stimulated with either LPS (100
ng/ml) or human TNF- (100 ng/ml) for 15 min in the presence of graded concentrations of DS-96 or PMB. Quantification of p38 MAPK was
performed using flow cytometry. (B) Forward-scatter/side-scatter profile and the gating for p38 MAPK-negative and -positive gates obtained on
unstimulated cells (negative control), respectively. Back gating on the p38 MAPK-positive cells (dark-shaded peak) maps to the polymorphonu-
clear population. (C to E) Inhibition of LPS-induced proinflammatory cytokine production in human blood. Whole human blood was stimulated
with 100 ng/ml LPS preincubated with graded concentrations of either DS-96 or PMB. Cytokine levels were quantified using a multiplexed
flow-cytometric bead array system (CBA). Only TNF-, IL-6, and IL-8 levels were quantifiable; IL-10 and IL-12p70 levels were below detection
limits, and signal-to-noise ratios for IL-1 were unacceptably high.
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Ex vivo neutralization activity in human blood. We sought
to verify that the endotoxin-sequestering activity of DS-96
would be manifested in the milieu of whole human blood,
characterized not only by its high ionic strength (300
mosmol), which attenuates electrostatic interactions (10), but
also by near-millimolar concentrations of albumin. Albumin
has been shown to bind both LPS (9) and DS-96 (unpublished
data). Also present in human serum are a number of high-
affinity LPS-binding proteins, such as soluble CD-14 (13) and
LPS-binding protein (1). Furthermore, given the amphipathic
nature of both LPS and DS-96, it is conceivable that substantial
partitioning of both the target and the ligand into the lipo-
protein constituents could occur, as has been observed with
E5564, a lipid A receptor antagonist currently undergoing clin-
ical trials (33). For these reasons and prior to initiating in vivo
evaluation, we compared the effects of DS-96 and PMB in two
ex vivo assays using whole human blood.
In the first, we examined the specificity and potency of
DS-96 relative to those of PMB in inhibiting the phos-
phorylation of p38 MAPK, a key component of a phosphor-
ylation cascade that is upstream of NF-B (20). Exposure of
whole blood obtained from healthy human volunteers to 100
ng/ml LPS results in a marked elevation in T180/Y182 dually
phosphorylated p38 MAPK as probed by flow cytometry
using a PE-labeled anti-phospho-p38 MAPK (T180/Y182)
antibody (Fig. 6A). The activation seems to occur chiefly in
polymorphonuclear (PMN) cells, since the positive popula-
tion maps directly to the subset of cells adjudged to be PMN
based on forward and side-scatter characteristics (Fig. 6B).
The addition of either PMB or DS-96 concomitant with LPS
exposure results in a concentration-dependent attenuation
of p38 MAPK phosphorylation, with the potencies of both
compounds being very similar. Notably, p38 MAPK phos-
phorylation induced by TNF- is affected by neither com-
FIG. 7. (A) Comparison of in vivo potencies of PMB and DS-96: dose-dependent increase in survival in mice challenged with a supralethal dose
of LPS (200 ng/animal). (B) Schild-type response in vivo: dose dependence of survival in mice challenged with escalating supralethal doses of LPS
(200, 500, or 1,000 ng/animal). The LD100 of LPS was determined to be 100 ng/mouse. (C) Time course (pharmacodynamics) of protection
conferred by 8 mg/kg of DS-96 administered subcutaneously at various times prior to and following supralethal (200 ng/mouse) LPS challenge.
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pound, emphasizing again the specificity of action against
LPS (Fig. 6A).
We next evaluated the efficacy of DS-96 in inhibiting pro-
inflammatory cytokine release in whole human blood, using a
multiplexed cytokine detection system (26). DS-96 inhibits
TNF-, IL-6, and IL-8 production with an IC50 of 3 to 5 M
(an LPS stimulus of 100 ng/ml was used), which is considerably
lower than that of PMB (11 to 13 M) (Fig. 6C to E). As
controls, we used phorbol myristate acetate (100 ng/ml) plus
ionomycin (1 M) or phorbol myristate acetate plus phyto-
hemagglutinin (2 g/ml) as non-LPS stimuli. Neither com-
pound inhibited TNF-, IL-6, or IL-8 appreciably up to con-
centrations of 40 M, verifying that the inhibition observed
was specific for LPS (data not shown). It should be noted that
detectable levels of neither IFN- nor IL-10 were observed in
the plasma samples with the 4-h LPS stimulation regime that
was employed in our studies. It would appear that the early
phase of LPS-induced stimulation is characterized predomi-
nantly by a proinflammatory profile, which is effectively sup-
pressed by LPS sequestrants, such as PMB and DS-96.
Efficacy in murine models of septic shock. A well-estab-
lished murine model of lethal septic shock (5, 24, 26) was
employed to compare the potencies of DS-96 and PMB. Pilot
experiments clearly showed virtually superimposable profiles
of dose-dependent survival when LPS was precomplexed first
with graded concentrations of either DS-96 or PMB and then
administered as a single intraperitoneal (i.p.) injection to D-
galactosamine-primed mice (data not shown). However, it was
important to verify that complexation of circulatory LPS could
occur under in vivo conditions (i.e., the compound would
sequester systemic LPS when given parenterally via another
route). We therefore employed an alternate model. Cohorts of
10 CF-1 mice per group, sensitized to the lethal effects of LPS
with D-galactosamine, were challenged with a supralethal dose
of LPS (2 LD100  200 ng/animal) administered i.p. This was
preceded by a subcutaneous (s.c.) injection of graded doses of
test compounds given 1 h prior to LPS challenge. Although
similar patterns of dose-dependent increases in survival were
observed for the two compounds, DS-96 afforded significantly
better protection than PMB at 4 mg/kg (Fig. 7A). We con-
firmed that the protection afforded by DS-96 was attributable
to attenuated LPS-induced cytokine production (Fig. 8). Fur-
thermore, DS-96 was without any effect on lethality induced
by 100 ng/animal of recombinant murine TNF- (data not
shown). As mentioned earlier, pharmacokinetic experiments
aimed at quantifying the half-lives of test compounds have on
occasion led to apparent incongruencies with pharmacody-
namics data due to unusual partitioning and/or protein-binding
behavior, as has been observed with E5564, for instance (33).
We elected therefore to first characterize the pharmacodynam-
ics of DS-96. Mice were administered DS-96 at a dose of 8
mg/kg s.c. at various time points before and after a supralethal
LPS challenge. As depicted in Fig. 7C, DS-96 is maximally
effective when it is administered concurrently with LPS admin-
istration; the data further suggest that sufficiently high plasma
concentrations apparently persist even up to 8 h so as to pro-
vide partial protection against LPS-induced lethality (Fig. 7C).
It should be noted that DS-96 is bereft of any protective effect
if administered following LPS challenge, suggesting that once
the innate immune system has responded to the presence of
FIG. 8. Time course of cytokine levels in mice receiving 4 mg/kg DS-96 and challenged with a 200-ng/ml dose of LPS. Cohorts of five animals
each received either 4 mg/kg DS-96 or saline s.c. at t  1 h, followed by D-galactosamine–LPS given i.p. at t  0 h. At t  1, 2, or 3 h, animals
were bled by terminal cardiac puncture, and cytokines were assayed in plasma by cytometric bead array assays. It should be noted that only TNF-,
IL-6, and macrophage chemotactic protein 1 levels were quantifiable; IL-10, IL-12p70, and IFN- levels were below detection limits.
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circulatory LPS, anti-endotoxin agents are unlikely to be of any
benefit. This is crucial since this defines the subset of patients
in whom a compound such as DS-96 is likely to be of benefit.
Toxicity. DS-96 is a cationic amphipath and, as such, is
expected to be surface active, with the possible consequence of
nonspecific cytotoxicity. Gratifyingly, we found that our appre-
hension was unwarranted: the hemolytic activity of DS-96 was
virtually abrogated in the presence of physiological concentra-
tions of albumin. In whole human blood, significant hemolytic
activity occurred only at millimolar concentrations (data not
shown). Daily s.c. administration of DS-96 to mice at a dose of
40 mg/kg per day for 5 days (note that full protection against
LPS-induced lethality was conferred with a single dose of 4
mg/kg) resulted in no clinically observable signs of apparent
toxicity. We paid particular attention to the development of
CNS toxicity in light of the fact that compounds such as N1-
dansylspermine and N1-(n-octanesulfonyl)spermine have been
reported to be potent N-methyl D-aspartate receptor antago-
nists (35, 36), and we have ourselves observed the rapid onset
of tonic-clonic seizures upon the systemic administration of
long-chain polyamine sulfonamides that we had evaluated (un-
published data). Importantly, at the end of the experiment (day
6), there were no demonstrable signs of nephro- or hepatotox-
icity as assessed by clinical chemistry (unpublished data). Sev-
eral polyamine derivatives have been shown to cause derange-
ment of polyamine metabolism as a consequence of polyamine
oxidase inhibition (41), (34), and we were therefore interested
in examining the effects of subacute high-dose treatment with
DS-96. No differences in polyamine levels (putrescine, spermi-
dine, spermine, N1-acetylspermidine) between control mice
and those that received 40 mg/kg per day DS-96 for 5 days were
noted (data not shown).
The experimental studies described in this paper establish
that DS-96 binds LPS and attenuates its toxicity with a potency
very similar to that of PMB. The inhibition of early cellular
activation events, namely, p38 MAPK phosphorylation and
NF-B translocation, in conjunction with the inhibition of the
more distal response events of cytokine and NO production
and the lack of activity against non-LPS stimuli clearly show
that the mechanism of action is via sequestration of LPS.
DS-96 was found to exhibit potent anti-endotoxin activities not
only in whole human blood ex vivo but also in a murine model
of endotoxic shock.
Particularly instructive are the results of the time course
experiment with mice (Fig. 7C), which show that if LPS-se-
questering compounds, such as DS-96, are ever to find utility in
the clinic, they will have to be used as prophylactic agents
rather than in treatment of established sepsis, for once the
inflammatory cascades are set in motion, LPS sequestrants
would be of no value. This may indeed be feasible and indeed
desirable, not only since many of the therapeutic strategies that
target downstream processes, such as blockade of TNF- or
IL-1, have failed (29, 46) but also because the predisposing
factors for septic shock are very well recognized (28). It may be
possible to institute LPS sequestrant therapy as an adjunct to
conventional antimicrobial chemotherapy—with the important
proviso that the therapeutic index is sufficiently high. We
therefore have examined the effects of large multiples of ther-
apeutic doses of DS-96 in the murine model and have not
found any detectable toxicity. Escalating dose regimens and
histopathology studies are currently in progress, as are phar-
macokinetic experiments using liquid chromatography-mass
spectrometry to determine the plasma half-life of the com-
pound.
In summary, we have described here a detailed character-
ization of DS-96, a novel monoalkylated homospermine de-
rivative, exhibiting true LPS-sequestering and -neutralizing
properties in a panel of in vitro assays and with a murine
model of endotoxic shock. The potency of DS-96 rivals that
of PMB and, in some key assays, including a murine model
of endotoxic shock, is superior to that of PMB.
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